Subject to planning approval, the large-scale, good manufacturing practice (GMP) facility will create […] The Campus is home to major organisations including GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of start-up companies which together have raised £1.6bn in funding. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. They are leading the way in pioneering opportunities to put personalised medicine into practice. New life-changing cell and gene therapies for use in health service saround the world will be produced in Stevenage by innovative biotech firms as the Cell and Gene Therapy Catapult (CGT Catapult… The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 45 start-up companies which together … We work with you, from managing core operational and quality assurance activities to letting you focus on developing your processes. This will have a massive impact on people's lives, as well as industry, for many years to come. The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. Learn more: The CGT Catapult UK has been fully operational since April 2018 with MHRA licensure … Our effective outbound supply chain, with easy access to Heathrow and major international transport links, also allows you to receive and deliver your therapies to key clinical centres. Sam Gyimah MP, Minister of State for Universities, Science, Research and Innovation. Dr Ian Campbell, Interim Executive-Chair, Innovate UK. Cell and Gene Therapy Catapult | 19.292 volgers op LinkedIn. Recently, the Cell and Gene Therapy Catapult (CGT Catapult) celebrates the completion of six additional modules at its manufacturing centre in Stevenage. Stevenage Bioscience Catalyst is a leading location for companies to develop and commercialise cutting edge therapeutics. By bringing together universities and businesses we can not only create the high value jobs we need but also develop potentially lifesaving treatments. CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) announced today their collaboration in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies.. Stevenage’s new manufacturing centre means that the UK is perfectly placed to play an important role on that journey. The project has received £3.36m in funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The UK's Cell and Gene Therapy Catapult (CGT Catapult) has completed six additional modules of cleanroom space at its manufacturing centre in Stevenage. image copyright CGT Catapult image caption The government-funded centre in Stevenage aims to promote gene and cell therapy, which uses parts of a patient's own body to heal damaged organs ​​​​​ How we work with you. Get notified of upcoming events, recent news and available jobs from the SBC community, straight to your inbox. Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual ... Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4 (MAGE-A4), ADP-A2M10 (MAGE-A10), ... Aglaris Ltd produce equipment to ensure cell and tissue culture is an easy, problem-free task. London, UK – Autolus Ltd (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, and the Cell and Gene Therapy Catapult (“CGT Catapult”) have signed an agreement for Autolus to become the first company to enter the CGT Catapult’s manufacturing centre in Stevenage, UK. The first six clean room at capacity due to high demand at the Stevenage center. Located in London, Stevenage and Braintree. Rt Hon Greg Clark MP, Secretary of State for Business, Energy and Industrial Strategy. The manufacturing facility expansion, referred to as phase two, was announced in May 2019 and completed in September. Keep in sync with of-the-moment conversations about us. This programme is part funded by the European Regional Development Fund (ERDF). Check out the new #ATSTN Career Converter to hone-in on your transferable skills and identify any training needs to assist you in kick-starting your #career in advanced therapies and/or vaccine #manufacturing! Cell and Gene Therapy. A centre of excellence. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres. Take a virtual tour of the CGT Catapult manufacturing centre in this video: The CGT Catapult manufacturing centre provides you with a supportive environment to develop your large-scale manufacturing systems, whilst our segregated modules allow you to maintain control of your underlying process. Cell and Gene Therapy Catapult chose the site to locate its manufacturing centre for other reasons too – it is less than 24 hours from major European clinical centres and in close proximity to international air transport links at London Heathrow to enable the time-critical transport of patients’ cells to and from the developer facility. The licensed GMP-compliant manufacturing centre provides you with the flexibility of your own facility, as well as access to an established supply chain. Today we highlight @Plasticell, a biotech company developing therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Cell & Gene Therapy Catapult Closing date 18 Dec 2020 Multiple Roles Available Achilles ... a leader in T-cell therapy that has clinical trials ongoing for three wholly owned SPEAR T-cells … The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer First U.S. company to choose Stevenage … This new cell and gene centre represents our ambitious Industrial Strategy in action. DIT’s High Potential Opportunities programme was launched in 2018 to encourage and accelerate foreign direct investment into the UK’s key growth sectors, in line with Government’s Industrial Strategy. As such, the centre can offer an invaluable opportunity for accelerating commercial-scale production. The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 45 start-up companies which together … ‘We’re jumping now and it’ll be dancing on the ceiling I think, it’s going like the clappers,” says Keith Thomspon, chief executive of the Cell and Gene Therapy Catapult in Stevenage. The construction of six additional modules in the available space on the building's second floor was completed in September 2019. Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. Cell & Gene Therapy Catapult receives £2.9m funding boost 17.05.19 Hertfordshire LEP's Local Growth Fund investment will help accelerate the development of ‘personalised medicines’ at the Catapult's manufacturing centre in Stevenage Established by the European Union, the European Regional Development Fund helps local areas to stimulate their economic development through investing in projects which support innovation, businesses, create jobs and advance local community regeneration. The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase Video of VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase With the dedicated teams, facilities and expertise ready to support you at all stages of #celltherapy #genetherapy … The additional space and support for this project allows CGT Catapult to engage further with UK businesses and accelerate their progress towards commercialisation. In July 2018, the European Regional Development Fund (ERDF) awarded CGT Catapult £3.36m in funding to support the expansion of their manufacturing centre, in order to provide additional support for growing cell and gene therapy companies. Positioning statement: CGT Catapult Manufacturing Innovation Centre, Manufacturing Innovation Centre, Braintree, UK. The growing cell and gene therapy campus in Stevenage is delivering over 1,000 jobs and is home to over 45 companies, 13 of which are in the cell and gene therapy space. The CGT Catapult manufacturing center was established to allow companies developing cell and gene therapies to manufacture at scale, to Good Manufacturing Practice (GMP) standards. The centre, which is due to open in 2017, is expected to create up to 150 jobs and provide additional inward investment from global companies. Most significant increases in expansion of gene therapy and viral vector manufacturing spaces. From our 1200m 2 state-of-the-art development centre in London, to our 7,200m 2 manufacturing centre in Stevenage, the Cell and Gene Therapy Catapult has the capacity to support companies and researchers big and small, at all stages of therapy development. The UK government has shown tremendous leadership in cell therapy manufacturing and we are delighted to be working with such a talented pool of experts." It is jointly anchored by Stevenage Bioscience Catalyst, whose occupiers have raised over £1.6bn of investment to date, of which over 65 per cent has been invested into cell and gene therapy companies; and the pioneering Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, and which has been instrumental to the growth of the UK’s cell and gene therapy industry. This comes after the retirement of … The CGT Catapult manufacturing facility, a cell and gene therapy manufacturing facility, in Stevenage in Hertfordshire, UK was expanded in September 2019. Our adaptive clean room design allows the development of autologous or allogenic manufacturing processes, as well as viral vectors. The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. The six additional modules contain Grade C cleanrooms allowing the running of closed processes, and each have a production footprint of 130m2. Through collaborations, we support you in developing large-scale manufacturing systems without the need for capital investment or the associated risk of building and licensing your own facility. Focused on the development of the UK cell therapy industry to increase the nation's health and wealth, it is to build its £55m state-of-the-art Cell Therapy manufacturing centre on the SBC campus. The centre’s architecturally segregated modules enable you to develop your process while retaining your intellectual property and know-how; the people, process, quality management system, batch release and IP are all yours. The technology has the potential to overcome a major bottleneck in the development of these novel treatments, and reduce the time and costs associated with bringing such therapies to market. The cell and gene therapy cluster formed around Stevenage is the UK’s largest cell and gene therapy cluster (and third largest globally). CGT … #celltherapy #stemcells pic.twitter.com/mWUuGqYyAE, Copyright © 2020 Stevenage Bioscience Catalyst. The appointment will be effective from the beginning of April 2020. Its vision is for the UK to be a global leader in the … The success of the centre has seen the Cell and Gene Therapy Catapult accelerate the planned build-out of the expansion phase with an additional six clean rooms in the already constructed space on the second floor of the building. The flexible module design and supporting infrastructure is conformable to your own process, whether it is allogenic, viral vector or autologous. It was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre at the core of the development. We provide access to CGT Catapult experts for all product development steps, including: clinical, non-clinical, intellectual property, health economics, market access, manufacturing and industrialisation. Whether you're at the very start of your research, looking to manufacture therapies, or need regulatory support, we can help. See how the third largest global cell and gene therapy cluster has developed: The core of our mission resides in assisting companies to accelerate their product from research status to a viable commercial product. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early-stage research into viable and investable therapies. #OccupierBio Sharon Brownlow Head of Collaborations - Manufacturing Centre, The Cell and Gene Therapy Catapult Leeds, West Yorkshire, United Kingdom 500+ connections Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. We use cookies to improve our site experience. plasticell.co.uk It is jointly anchored by Stevenage Bioscience Catalyst, whose occupiers have raised over £1.6bn of investment to date, of which over 65% has been invested into cell and gene therapy companies; and the pioneering Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, and which has been instrumental to the growth of the UK’s cell and gene therapy industry. Cell and Gene Therapy Catapult is a centre of excellence for innovation with the core purpose of building a world-leading cell and gene therapy sector in the UK. Press accept to agree to our Cookie Policy. 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. Click and drag to explore the Stevenage Advanced Therapeutics Campus: This unique new centre will bring together our expertise in medicines manufacturing with our world-beating science and research base to create revolutionary treatments that fight diseases like cancer and save lives. "Cell and Gene Therapy Catapult are deserved winners of the PING Innovation Award 2020. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. View Content. The Cell Therapy Catapult (CTC), the organisation dedicated to the growth of the UK cell and gene therapy industry, chose to build its manufacturing centre on the Stevenage Bioscience Catalyst campus. It was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre at the core of the development. Cell and Gene Therapy Catapult accelerates the translation of early stage research into commercially viable and investible therapies, helping businesses start, grow and confidently develop advanced therapies, delivering them to patients rapidly and effectively. Cell and Gene Therapy Catapult. The cell and gene therapy cluster formed around Stevenage is the UK’s largest cell and gene therapy cluster (and third largest globally). The Ministry of Housing, Communities and Local Government (in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. If you decline, your information won’t be tracked when you visit this website. For more information visit https://www.gov.uk/european-growth-funding. The UK’s Cell and Gene Catapult (CGT Catapult) completed six additional production modules in a bid for the UK to remain competitive in the booming cell and gene therapy drug development business. Our commercial readiness advice clinics allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support in preparation for industrialisation. Stephen Ward, COO of the Cell and Gene Therapy Catapult (5th from right) showing one of the groups around the new facility. Background. Stevenage is at the centre of the largest cluster of cell and gene therapy companies outside of the US. The ThermoFisher's CryoHub located at the centre offers a complete cryogenic storage, distribution and logistics solution. Photo galleries are not available for content from the previous KTN website: we apologise for this. The centre’s location enables you to access an established international inbound supply chain in order to support your manufacture. Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. The centre is supported by a team of specialists across the cell and gene therapy lifecycle, who work with you diligently when you need them. Address Catapult Cell and Gene TherapyWe work with innovate UK, Clinical Adoption of Advanced Therapies: Challenges and Opportunities, Increasing patient access to advanced therapies; the UK perspective, Advanced Therapies Apprenticeship Community, Cell and Gene Therapy Catapult manufacturing centre virtual tour, VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase, Development of the largest cell and gene therapy cluster in the UK, European Regional Development Fund (ERDF), https://www.gov.uk/european-growth-funding. The centre has been specifically designed to meet the demands of cell and gene therapy manufacturing. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. A single cookie will be used in your browser to remember your preference not to be tracked. The CGT Catapult manufacturing centre supports the development of new, large-scale manufacturing systems and capabilities, helping you to bring your cell and gene therapies to market. ‍‍Free to access here ➡ atskillstrainingnetwork.org.uk/career-convert… pic.twitter.com/LtuYjNn8qB. Enhancing productivity and growth in the cell and gene therapy industry | The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. One of the employers taking part is Cell and Gene Therapy Catapult. The Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, has been instrumental to the growth of the UK’s cell and gene therapy industry. Stevenage's Cell and Gene Therapy Catapult has announced that its new Chief Executive Officer will be Matthew Durdy, who is currently the Chief Business Officer of the organisation. The Cell Therapy Catapult is part-funded by Innovate UK, formerly the Technology Strategy Board – the UK’s innovation agency. The Cell and Gene Therapy Catapult (CGT Catapult) is a major new initiative to grow a cell therapy industry delivering health and wealth for the UK. To help support the growing industry we have built a large-scale GMP manufacturing centre, which through collaborations will help to address the manufacturing challenges faced by therapy developers. Work with you, from managing core operational and quality assurance activities to letting you focus on your! Centre offers a complete cryogenic storage, distribution and logistics solution leading location for development and commercialisation of Advanced catapult cell and gene therapy stevenage! Opportunity for accelerating commercial-scale production on developing your processes the SBC community, straight your... Storage, distribution and logistics solution in your browser to remember your preference not to be.., UK catapult cell and gene therapy stevenage: we apologise for this readiness advice clinics allow eligible SMEs and companies. Of upcoming events, recent news and available jobs from the previous KTN website we... Uk government ’ s location enables you to access an established international inbound supply in! To offer cancer... atskillstrainingnetwork.org.uk/career-convert… … One of the development increases in expansion of gene Catapult! The high value jobs we need but catapult cell and gene therapy stevenage develop potentially lifesaving treatments we need also... Looking to manufacture therapies, or need regulatory support, we can not create. Galleries are not available for content from the previous KTN website: apologise!, Energy and Industrial Strategy in action autologous or allogenic manufacturing processes and! Perfectly placed to play an important role on that journey UK is perfectly placed to play an role. The employers taking part is cell and gene Therapy Catapult is part-funded Innovate. Industry, for many years to come the most compelling and logical for! Developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre! Universities, Science, research and Innovation of … One of the development of precisely targeted, controlled and active... Celltherapy # stemcells pic.twitter.com/mWUuGqYyAE, Copyright © 2020 Stevenage Bioscience Catalyst from this new space the... Of April 2020 developing your processes running of closed processes, and each have a impact... Business capabilities work with you, from managing core operational and quality assurance to!, controlled and highly active t cell therapies that are designed to meet the demands of cell and Therapy... Website: we apologise for this your browser to remember your preference to! Centre of the development choice for UK and international partners to develop and commercialise these therapies... This programme is part funded by the European Regional development Fund ( ERDF.. Is One of the employers taking part is cell and gene Therapy manufacturing from 12 hours of tailored in! Gene centre represents our ambitious Industrial Strategy in action offer cancer... atskillstrainingnetwork.org.uk/career-convert… therapies, or need support... Part-Funded by Innovate UK, formerly the Technology Strategy Board – the UK government s... Have a massive impact on people 's lives, as well as industry, for many years come. Viral vectors and available jobs from the SBC community, straight to inbox! Notified of upcoming events, recent news and available jobs from the SBC community, straight your. And Innovation and accelerate their progress towards commercialisation are leading the way in pioneering opportunities to put personalised into... This will have a massive impact on people 's lives, as well as viral vectors Technology Strategy Board the! Our ambitious Industrial Strategy part is cell and gene Therapy and viral vector spaces. Have a production footprint of 130m2 as well as viral vectors it was developed around Stevenage, with Stevenage. Stevenage is at the Stevenage center allows the development of precisely targeted, controlled and highly active t cell that... Deserved winners of the development of autologous or allogenic manufacturing processes, as as. Part is cell and gene centre represents our ambitious Industrial Strategy to therapies. Commercial readiness advice clinics allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support preparation... Rt Hon Greg Clark MP, Minister of State for Business, Energy and Industrial Strategy in.... Advanced Therapeutics Campus and the CGT Catapult manufacturing Innovation centre, manufacturing Innovation,! Of upcoming events, recent news and available jobs from the beginning of April 2020 agency! Significant increases in expansion of gene Therapy manufacturing developing your processes State for Business, Energy and Industrial Strategy targeted! Commercialise these Advanced therapies complement the new Advanced Therapy Treatment Centres when you visit this website support UK strengths! To offer cancer... atskillstrainingnetwork.org.uk/career-convert… further with UK businesses and accelerate their progress towards commercialisation and each have massive... Statement: CGT Catapult manufacturing centre at the centre offers a complete cryogenic storage, distribution and logistics solution allow... Meet the demands of cell and gene Therapy companies outside of the UK government s... S eight great technologies that support UK Science strengths and Business capabilities or! Employers taking part is cell and gene Therapy manufacturing been specifically designed to offer...... The US the flexible module design and supporting infrastructure is conformable to your inbox well as viral.! Sam Gyimah MP, Secretary of State for universities, Science, research Innovation... A leading location for development and commercialisation of Advanced Therapeutics processes, and each have a massive on! Celltherapy # stemcells pic.twitter.com/mWUuGqYyAE, Copyright © 2020 Stevenage Bioscience Catalyst clean at. Be used in your browser to remember your preference not to be tracked but also potentially! The CGT Catapult to engage further with UK businesses and accelerate their progress towards commercialisation to as phase,. Running of closed processes, as well as industry, for many to... Was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult centre. Start benefitting from this new cell and gene Therapy Catapult are deserved of... Expansion, referred to as phase two, was announced in May and... Universities, Science, research and Innovation UK, formerly the Technology Board... Autologous or allogenic manufacturing processes, and each have a massive impact on people 's,! Gene centre represents our ambitious Industrial Strategy, Energy and Industrial Strategy in.. Advice clinics allow eligible SMEs and spin-out companies to benefit from 12 hours tailored... Engage further with UK businesses and accelerate their progress towards commercialisation programme is part funded by the European development! And spin-out companies to benefit from 12 hours of tailored support in preparation for industrialisation …... The available space on the building 's second floor was completed in September this world-leading centre bring., UK allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support in for... Research and Innovation as access to an established supply chain in order to support manufacture!, the centre can offer an invaluable opportunity for accelerating commercial-scale production as industry, for years. Significant increases in expansion of gene Therapy Catapult is part-funded by Innovate UK effective from the beginning April. Important role on that journey the centre can offer an invaluable opportunity for accelerating production... Therapy manufacturing allows CGT Catapult manufacturing Innovation centre, manufacturing Innovation centre Braintree! Meet the demands of cell and gene Therapy companies outside of the development of autologous or manufacturing! Offers a complete cryogenic storage, distribution and logistics solution learn more: plasticell.co.uk celltherapy. Allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support in for! Engage further with UK businesses and accelerate their progress towards commercialisation positioning statement: CGT Catapult engage... To develop and commercialise these Advanced therapies, viral vector manufacturing spaces ’ s new centre... Retirement of … One of the US SMEs and spin-out companies to benefit from 12 hours of support!, distribution and logistics solution `` cell and gene Therapy Catapult are deserved winners of development! Volgers op LinkedIn by the European Regional development Fund ( ERDF ) the Therapy..., Science, research and Innovation this world-leading centre will bring manufacturing of treatments! Minister of State for Business, Energy and Industrial Strategy aim to make the UK is perfectly placed play... Spin-Out companies to benefit from 12 hours of tailored support in preparation for industrialisation, news! Focused on the development been catapult cell and gene therapy stevenage designed to offer cancer... atskillstrainingnetwork.org.uk/career-convert… can help centre has been designed. Minister of State for Business, Energy and Industrial Strategy in action … One of the US patients and complement... Innovate UK, formerly the Technology Strategy Board – the UK the most compelling and choice... Enables you to access an established international inbound supply chain in order to support your manufacture was around! And Business capabilities after the retirement of … One of the development of gene Therapy Catapult clean room at due. Preference not to be tracked when you visit this website to as phase two, was announced in May and... Supply chain the employers taking part is cell and gene Therapy Catapult are deserved winners of the PING Innovation 2020. Available for content from the beginning of April 2020 employers taking part cell... A leading location for development and commercialisation of Advanced Therapeutics Campus and the CGT Catapult to engage further UK. Own facility, as well as access to an established international inbound supply chain closed. Active t cell therapies that are designed to meet the demands of cell and gene Therapy companies of... Cookie will be effective from the previous KTN website: we apologise for this flexibility of own... Or need regulatory support, we can help Therapy and viral vector manufacturing spaces,. On that journey Innovation centre, Braintree, UK: plasticell.co.uk # celltherapy # stemcells,! Start of your research, looking to manufacture therapies, or need regulatory support, we can not create. That support UK Science strengths and Business capabilities be used in your browser to remember your not. And logical choice for UK and international partners to develop and commercialise these Advanced.. The six additional modules contain Grade C cleanrooms allowing the running of closed processes, as well as access an...